Event Brief
UPDATED Apr 6, 2026 at 12:09 PM ET
Apr 6, 2026 at 12:03 AM ET
Neurocrine invests $3bn in hunger treatment deal
By The BriefBrief
Neurocrine Biosciences acquires Soleno Therapeutics' drug for Prader-Willi syndrome.
WHO: Neurocrine Biosciences
WHAT: acquires Soleno Therapeutics' drug
WHEN: Apr 6, 2026 at 8:04 AM ET
WHERE: USA
WHY: To address extreme hunger caused by Prader-Willi syndrome.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Amazon faces months of repairs after drone strikes
Amazon
May 1, 2026 at 3:23 PM ET
Minnesota bans fake AI nudes; app makers face $500K
Minnesota
May 1, 2026 at 3:23 PM ET
Page 21439 of 21439
Same format. Every time.
Continue reading — sign in or create a free account with
